Senores Pharmaceuticals through its wholly-owned subsidiary -- Senores Pharmaceuticals, Inc., USA (SPI) has signed agreement to acquire two products of USFDA approved Abbreviated New Drug Applications (ANDAs) from Teva Pharmaceuticals USA, Inc.
The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by the company. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.
Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.
